Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Trial to Confirm the Efficacy of Olaparib in Combination With Bevacizumab as Frontline Treatment of HRD Positive Ovarian Tumors

NCT06121401 is registered in ClinicalTrials.gov with Mario Negri Institute for Pharmacological Research as lead sponsor.

NCT NCT06121401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06121401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Trial to Confirm the Efficacy of Olaparib in Combination With Bevacizumab as Frontline Treatment of HRD Positive Ovarian Tumors
Lead sponsor
Mario Negri Institute for Pharmacological Research
Phase
Phase 4
Overall status
Active, not recruiting
Start date
September 15, 2023
Completion date
September 15, 2027
Enrollment
190 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, ovarian epithelial